FOR BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS
Taltz vs Humira: Complete resolution of enthesitis at weeks 24 and 5210
Enthesitis data were prespecified but not type-I error-controlled; therefore, results cannot be regarded as statistically significant.
A subset of patients from SPIRIT-H2H with enthesitis (LEI >0) at baseline.
Primary endpoint=simultaneous achievement of ACR50 and PASI 100 at week 24.8
Mean baseline LEI scores were 2.5 for Taltz and 2.7 for Humira.8
All patients had BSA ≥3%; patients with BSA ≥10%, PASI ≥12, and sPGA ≥3 followed the dosing regimen indicated for moderate to severe PsO.
SELECT IMPORTANT SAFETY INFORMATION
HYPERSENSITIVITY
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.
FOR BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS
Taltz vs Humira: Complete resolution of dactylitis at weeks 24 and 5211
Dactylitis data were prespecified but not type-I error-controlled; therefore, results cannot be regarded as statistically significant.
A subset of patients from SPIRIT-H2H with dactylitis (LDI-B >0) at baseline.
Primary endpoint=simultaneous achievement of ACR50 and PASI 100 at week 24.8
Mean baseline LDI-B scores were 40 for Taltz and 56 for Humira.8
All patients had BSA ≥3%; patients with BSA ≥10%, PASI ≥12, and sPGA ≥3 followed the dosing regimen indicated for moderate to severe PsO.
SELECT IMPORTANT SAFETY INFORMATION
INFLAMMATORY BOWEL DISEASE
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.
FOR BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS
Superior PASI 100 response vs Humira at week 24, with consistency at week 5212
*P≤.001 vs Humira at week 24 for PASI 100.12
†P≤.001 vs Humira at week 52 for PASI 100.12 Nominal P value: Week 52 was not controlled for type-I error; therefore, no statistical comparisons can be made.
Primary endpoint=simultaneous achievement of ACR50 and PASI 100 at week 24.8
All patients had BSA ≥3%; patients with BSA ≥10%, PASI ≥12, and sPGA ≥3 followed the dosing regimen indicated for moderate to severe psoriasis.8
SELECT IMPORTANT SAFETY INFORMATION
IMMUNIZATIONS
Prior to initiating Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
IN BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS
Safety profile of Taltz in SPIRIT-H2H is consistent with registration trials; no new safety signals were observed8,13,14
The most frequent injection site reactions were erythema and pain. Most injection site reactions were mild to moderate in severity.14
Certain adverse events, such as MACE, malignancy, and cerebrocardiovascular events, require longer observation periods and larger patient exposure to ascertain risk. Lilly is conducting continued long-term safety studies, including post-marketing studies, to continue to evaluate the safety of Taltz.
*Safety data show all results available at the time of the last patient reaching week 24, including results to week 52.
†Patients with uncontrolled ulcerative colitis (UC) or Crohn’s disease were excluded from the studies; however, patients with a personal or family history of UC/Crohn’s were allowed in the study.
‡Confirmed by adjudication.
FOR BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS
SPIRIT-H2H:
Taltz vs Humira
TALTZ DEMONSTRATED:
- Superiority vs Humira in the percentage of patients who achieved both ACR50 and PASI 100 at week 24, with consistency at week 521,6
- Complete resolution in key domains of PsA2-4,10-12
(Enthesitis, dactylitis, plaque psoriasis)
Click here for data - Safety consistent with registration trials5,8,13,14
Click here for data
SPIRIT-P1 and P2 Registration Trial Data
TALTZ HAS NO BOXED WARNING.14
Think Psoriatic Arthritis. Think Taltz.
SELECT IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis, and conjunctivitis, influenza, and urticaria in pediatric psoriasis.
References: 1. Data on file. Lilly USA, LLC. DOF-IX-US-0121. 2. Data on file. Lilly USA, LLC. DOF-IX-US-0122. 3. Data on file. Lilly USA, LLC. DOF-IX-US-0123. 4. Data on file. Lilly USA, LLC. DOF-IX-US-0124. 5. Data on file. Lilly USA, LLC. DOF-IX-US-0125. 6. Data on file. Lilly USA, LLC. DOF-IX-US-0190. 7. Data on file. Lilly USA, LLC. DOF-IX-US-0119. 8. Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79:123-131. 9. Data on file. Lilly USA, LLC. DOF-IX-US-0189. 10. Data on file. Lilly USA, LLC. DOF-IX-US-0194. 11. Data on file. Lilly USA, LLC. DOF-IX-US-0195. 12. Data on file. Lilly USA, LLC. DOF-IX-US-0191. 13. Data on file. Lilly USA, LLC. DOF-IX-US-0188. 14. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020. 15. Mease PJ, van der Heijde D, Ritchlin CT, et al; on behalf of SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase 3 trial SPIRIT-P1. Ann Rheum Dis. 2017;76(suppl):1-30. 16. Nash P, Kirkham B, Okada M, et al; on behalf of SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317-2327. 17. Nash P, Kirkham B, Okada M, et al; on behalf of SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317-2327. Supplementary appendix.